Risk factors for second solid cancers, according to age at transplantation and type of solid cancer, among survivors for 1 or more years after HCT
| Variable . | All solid cancers . | Non-SCCs . | SCCs . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No. cases . | RR . | 95% CI . | No. cases . | RR . | 95% CI . | No. cases . | RR . | 95% CI . | |
| Age < 30 y at HCT | n = 98 | n = 67 | n = 31 | ||||||
| No radiation | 14 | 3 | 11 | ||||||
| TBI | 78 | 3.34† | 1.51-7.93 | 62 | 8.87† | 2.51-45.25 | 16 | 1.12 | 0.33-3.83 |
| LFI, no TBI | 6 | 3.63† | 1.11-11.42 | 2 | 10.40† | 1.27-85.02 | 4 | 1.80 | 0.43-6.97 |
| Chronic GVHD* | 28 | 1.39 | 0.87-2.16 | 8 | 0.46† | 0.20-0.93 | 20 | 6.34† | 3.04-13.92 |
| Age ≥ 30 y at HCT | n = 67 | n = 43 | n = 24 | ||||||
| No radiation | 17 | 10 | 7 | ||||||
| TBI | 47 | 1.09 | 0.58-2.15 | 31 | 1.08 | 0.49-2.60 | 16 | 1.08 | 0.40-3.40 |
| LFI, no TBI | 3 | 3.11 | 0.53-16.06 | 2 | 2.58 | 0.31-15.74 | 1 | 7.21 | 0.15-164 |
| Chronic GVHD* | 28 | 1.72† | 1.02-2.86 | 13 | 1.01 | 0.49-1.97 | 15 | 4.07† | 1.75-9.96 |
| Variable . | All solid cancers . | Non-SCCs . | SCCs . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No. cases . | RR . | 95% CI . | No. cases . | RR . | 95% CI . | No. cases . | RR . | 95% CI . | |
| Age < 30 y at HCT | n = 98 | n = 67 | n = 31 | ||||||
| No radiation | 14 | 3 | 11 | ||||||
| TBI | 78 | 3.34† | 1.51-7.93 | 62 | 8.87† | 2.51-45.25 | 16 | 1.12 | 0.33-3.83 |
| LFI, no TBI | 6 | 3.63† | 1.11-11.42 | 2 | 10.40† | 1.27-85.02 | 4 | 1.80 | 0.43-6.97 |
| Chronic GVHD* | 28 | 1.39 | 0.87-2.16 | 8 | 0.46† | 0.20-0.93 | 20 | 6.34† | 3.04-13.92 |
| Age ≥ 30 y at HCT | n = 67 | n = 43 | n = 24 | ||||||
| No radiation | 17 | 10 | 7 | ||||||
| TBI | 47 | 1.09 | 0.58-2.15 | 31 | 1.08 | 0.49-2.60 | 16 | 1.08 | 0.40-3.40 |
| LFI, no TBI | 3 | 3.11 | 0.53-16.06 | 2 | 2.58 | 0.31-15.74 | 1 | 7.21 | 0.15-164 |
| Chronic GVHD* | 28 | 1.72† | 1.02-2.86 | 13 | 1.01 | 0.49-1.97 | 15 | 4.07† | 1.75-9.96 |
Multivariate Poisson regression models were based 165 solid cancers including 18 invasive SCCs of the skin and 13 nonskin carcinomas in situ; analyses were stratified by registry (FHCRC, CIBMTR), age (< 10, 20-29, 30-39, 40-49, ≥ 50 y), latency (1 to < 5, 5 to < 10, 10 to < 15, ≥ 15 y after HCT), and primary disease (ALL, ANLL, CML, SAA, other). Analyses excluded patients with unknown radiation or unknown radiation dose.
Chronic GVHD was moderate or severe grade in CIBMTR patients, or clinically extensive in FHCRC patients.
P < .05.